We are live on ! Find out more
ACHL

Achilles Therapeutics

Delisted

ACHL was delisted on the 20th of March, 2025.

0 hedge funds and large institutions have $0 invested in Achilles Therapeutics in 2026 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 3 → 0 (-3)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $98.9K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
–
Holders Change
-3
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

ACHL Hedge Fund Activity: Q3 2026 in Review

0 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q3 2026, worth a combined $0 — down 100% from $98.9K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ACHL and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Trium Capital, exiting entirely with an estimated $91K sold.

  • 0 institutional investors held Achilles Therapeutics (ACHL) as of Q3 2026, down from 3 in Q2 2026.
  • Funds reported $0 of Achilles Therapeutics stock for Q3 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Achilles Therapeutics positions in Q3 2026 and 3 closed out, a net change of -3 holders.
  • The largest Achilles Therapeutics seller in Q3 2026 was Trium Capital, an estimated $91K sold.

Based on aggregated 13F filings for Q3 2026.